Quantum BioPharma (QNTM) submits Form 6-K with press release exhibit

Rhea-AI Filing Summary

Quantum BioPharma Ltd. (symbol QNTM) filed a routine Form 6-K on 27 June 2025. The filing’s sole purpose is to furnish a press release, dated the same day, as Exhibit 99.1. No financial statements, earnings data, or transaction details are included in this submission. The document confirms the company continues to file its annual report on Form 20-F and bears the signature of Chief Financial Officer Donal Carroll.

Insights

Financial Analyst

TL;DR – Routine regulatory filing; no new financial data.

This 6-K merely places a press release on the public record without disclosing numbers, guidance, or strategic actions. Absent the press release’s contents, investors gain no material insight, so market impact should be minimal.

Corporate Governance Expert

TL;DR – Proper compliance; governance risk unchanged.

The company met SEC requirements by promptly furnishing Exhibit 99.1 and clearly indicating signature authority. No governance red flags or irregularities appear in the filing, keeping overall risk profile neutral.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-39152

Quantum BioPharma Ltd.
(Translation of registrant's name into English)

55 University Ave., Suite 1003
Toronto, Ontario M5J2H7, Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Quantum BioPharma Ltd.
		(Registrant)
Date: June 27, 2025		/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated June 27, 2025

FAQ

What did Quantum BioPharma (QNTM) file on June 27, 2025?

The company furnished a Form 6-K to supply a press release dated June 27 2025.

Does the 6-K contain any financial statements or earnings data?

No. The filing only references an attached press release; no financial tables are included.

Who signed the Form 6-K for Quantum BioPharma?

Donal Carroll, Chief Financial Officer, signed the document.

Which annual report form does Quantum BioPharma file?

The company files its annual reports under Form 20-F.

What is Exhibit 99.1 in the filing?

Exhibit 99.1 is the press release issued by the company on June 27 2025.